MARIPOSA-2

The MARIPOSA 2 Research Study

An Overview for Healthcare Professionals

The information contained in this download is intended for healthcare providers only.
This is not to be used with potential participants.

About the MARIPOSA 2 Study

The purpose of the MARIPOSA 2 research study is to evaluate the combined efficacy of the investigational medications amivantamab and lazertinib versus chemotherapy in adults with locally advanced or metastatic non-small-cell lung cancer (NSCLC) that have epidermal growth factor receptor (EGFR) Exon 19 deletion or Exon 21 L858R substitution mutations.

Your patients may be eligible if they meet the following inclusion criteria:

- ≥18 years of age
- Have histologically or cytologically confirmed, locally advanced or metastatic non-squamous NSCLC not amenable to curative therapy
- Have a tumor that was previously determined to have EGFR Exon 19 deletion or Exon 21 L858R substitution
- Have experienced disease progression on or after taking osimertinib monotherapy as the most recent line of treatment
- Have not received an investigational medication within 12 months before randomization or be currently enrolled in an investigational study

MARIPOSA-2

What will happen during the MARIPOSA 2 Study?

- Eligible patients will be randomized 2:2:1 to Arms A, B, and C, respectively
  - Participants in Arm A will receive the investigational combination of lazertinib, amivantamab, carboplatin, and pemetrexed (all intravenous infusions except lazertinib, taken orally)
  - Participants in Arm B will receive carboplatin and pemetrexed (both intravenous infusions)
  - Participants in Arm C will receive the investigational combination of amivantamab along with carboplatin and pemetrexed (all intravenous infusions)
- All participants will go through 21-day cycles with their investigational medication
- The length of a patient's overall study participation will depend on the response to the investigational medications and subsequent medications
- Participation also includes regularly scheduled study visits for tests and procedures

Each study participant will continue on 21-day treatment cycles until their NSCLC progresses, unacceptable toxicity occurs, the study ends, or they discontinue for other reasons.

There are study clinics located throughout the United States. Find a location near you by visiting https://janssenoncologyclinicaltrials.com/lc/m2/hcp-locations

To see a list of participating study clinics in over 20 countries globally, visit https://janssenoncologyclinicaltrials.com/lc/m2/hcp-countries

If you have a patient with EGFR Exon 19 deletion or Exon 21 L858R substitution mutations who may be a candidate, speak to them about the possibility of participating in this research study.

Have your patients call **844-942-0216** or visit
janssenoncologyclinicaltrials.com/lc/m2/hcp-study
to see if they are eligible and to learn more
about the **MARIPOSA 2** Study.

Janssen Research & Development, LLC
61186372NSC3002_ENG21
Version 1.0, 09July2021

janssen Oncology
PHARMACEUTICAL COMPANIES OF Johnson&Johnson